Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19
- PMID: 33028665
- DOI: 10.1136/gutjnl-2020-322929
Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19
Keywords: acute liver failure.
Conflict of interest statement
Competing interests: MI: speaking/teaching, consultant and advisory board for Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, Guerbet, EISAI. RD’A: teaching and speaking for AbbVie, Gilead, MSD; Advisory Board for AbbVie, MSD, Research Grant from Gilead. PL: advisory board/speaker bureau for BMS, Roche, Gilead, GSK, AbbVie, MSD, Arrowhead, Alnylam, Janssen, Spring Bank, MYR, Eiger.
Comment on
-
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.Gut. 2021 Mar;70(3):531-536. doi: 10.1136/gutjnl-2020-322118. Epub 2020 Jul 13. Gut. 2021. PMID: 32660964 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials